Lineage Cell Therapeutics (LCTX)
(Real Time Quote from BATS)
$0.92 USD
+0.01 (1.10%)
Updated Sep 20, 2024 12:32 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LCTX 0.92 +0.01(1.10%)
Will LCTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
Other News for LCTX
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance?, at the 59th Annual Inner Ear Biology Workshop
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline Progress
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Lineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical Progress
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript